Key facts
- It has raised $53.4M.
- Notable investors include Indaco Venture Partners, XGEN Venture.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tes Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Tes Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tes Pharma
Operator of a research-based biopharmaceutical company intended to deliver proprietary drug candidates for oncology, renal and metabolic diseases. The company specializes in cellular and molecular biology and medicinal, computational and analytical chemistry in the discovery and development of innovative therapies, enabling clients to realize the potential of novel therapeutic targets, including orphan nuclear receptors.
- Sector
- Healthcare
- HQ
- Perugia, Italy
- Founded
- 2011
- Employees
- 25
- Website
- tespharma.com/
- Ownership
- Privately Held (backing)
Tes Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tes Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tes Pharma in its N-PORT filings yet. We sweep new filings monthly.